Risperidone Pretreatment Prevents Elevated Locomotor Activity Following Neonatal Hippocampal Lesions
Open Access
- 15 June 2005
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (1) , 77-89
Abstract
Long-standing behavioral abnormalities emerge after puberty in rats following neonatal hippocampal lesion, providing a developmental model of abnormal rat behavior that may have predictive validity in identifying compounds effective in treating symptoms of schizophrenia. We sought to test the predictive validity of the neonatal hippocampal lesion model in identifying preventive treatment for first-episode psychosis. We determined the effect of risperidone, recently studied for prevention of first-episode psychosis, on the development of elevated locomotor activity following neonatal hippocampal lesions. Rat pups received hippocampal or sham lesions on postnatal day 7, followed by treatment with risperidone or vehicle from postnatal days 35 to 56. Locomotor activity in response to novelty, amphetamine, and nocturnal locomotion were determined on postnatal day 57. Low-dose risperidone (45 μg/kg) pretreatment prevented elevated locomotor activity in some, but not all, of the behavioral tasks following neonatal hippocampal lesions. In contrast, higher risperidone pretreatment was less effective in preventing elevated locomotor activity following neonatal hippocampal lesions. Because low risperidone dosages were also found to be effective in preventing first-episode psychosis in human studies, these data support the predictive validity of the hippocampal lesion model in identifying medications for prevention of first-episode psychosis. Additionally, these data support the use of low-dose risperidone in psychosis prevention, and suggest the possibility that higher risperidone doses could be less effective in this application.Keywords
This publication has 79 references indexed in Scilit:
- Effects of neonatal ventral hippocampal lesion in rats on stress‐induced acetylcholine release in the prefrontal cortexJournal of Neurochemistry, 2004
- Cognitive therapy for the prevention of psychosis in people at ultra-high riskThe British Journal of Psychiatry, 2004
- Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site AgonistsNeuropsychopharmacology, 2003
- Glutamatergic Mechanisms in SchizophreniaAnnual Review of Pharmacology and Toxicology, 2002
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- Endogenous retroviruses and schizophreniaBrain Research Reviews, 2000
- The Role of Serotonin in Antipsychotic Drug ActionNeuropsychopharmacology, 1999
- Enhancement of Postsynaptic Sensitivity to Dopaminergic Agonists Induced by Neonatal Hippocampal LesionsNeuropsychopharmacology, 1997
- Gonadectomy does not prevent novelty or drug-induced motor hyperresponsiveness in rats with neonatal hippocampal damageDevelopmental Brain Research, 1994
- The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activityJournal of Neural Transmission, 1993